In previous studies on RCC, we demonstrated that knockdown of PAX2 enhances cisplatin-induced apoptosis in RCC cells, suggesting that targeting of PAX2 could be a potential therapeutic approach [12]. This evidence concerns the gene PAX2 and renal cell carcinoma.